The foundation Milken started in 1993, the Association for the Cure of Cancer of the Prostate (CaP CURE), has approached this ambitious goal from two directions: funding a wide range of peer-reviewed prostate cancer research projects and bringing investigators, politicians, and businesspeople together to bring more attention and money to fighting the disease. CaP CURE is now the second-largest funder of prostate cancer research in the United States, foundation officials claim, behind only the National Cancer Institute (NCI).
Perhaps as important, according to its grantees, supporters, and observers, are the novel studies the Santa, Monica, Calif.-based foundation finances and its streamlined application review and approval process. "Prostate cancer is hot," observes Kenneth Tew, chairman of pharmacology at the Fox Chase Cancer Center in Philadelphia, whose research focuses on hormone-refractory prostate cancer. "In the past three to five years, a tremendous number of investigators have flocked into the field, and what ...
